Acacia Pharma has developed a late-stage pipeline of hospital nausea and vomiting product candidates based on repurposing existing drugs in new therapeutic indications. The Group’s product candidates are differentiated from the original marketed drug by using a different delivery method and/or dose that is appropriate for its new therapeutic use. Clinical proof of concept has been demonstrated.
Repurposing allows the Group to reference existing safety and pharmacological data on the active ingredients, which may reduce the time required to achieve clinical proof of concept in the new indication and the quantity of data needed for regulatory approval. This in turn lowers development costs and provides a higher probability of success compared to the development of new molecular entities.